Laboratory Corporation of America Holdings’ (LH) Prenatal Tests May be Inaccurate
On January 1, 2022, an article from the New York Times called into question the accuracy of certain noninvasive prenatal tests, including that developed by Labcorp. The article alleges that positive results on tests are incorrect about 85% percent of the time. Patients who receive a positive result are supposed to pursue follow-up testing, which “can cost thousands of dollars, come with a small risk of miscarriage and can’t be performed until later in pregnancy.” The investigation highlights the statistical challenge of testing from things that are extremely rare. But, this isn’t adequately explained to patients who were sold the tests. Companies that develop these tests use language like “highly accurate” and “total confidence,” do not publish data on their tests’ overall performance, or only stress data from tests that are more accurate.
On this news, Labcorp’s stock fell over $16.00, or 5%, to close at $298.18 per share on January 3, 2022, injuring investors.
Laboratory Corporation of America Holdings (LH) shareholders have legal options. If you own shares of Labcorp, contact us for more information about your legal options.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
